全球慢病管理形势严峻。据华经产业研究院发布的《2025-2031年中国慢病管理行业市场深度分析及投 资前景展望报告》数据显示，2024年全球死于慢性病人数约4273万人。目前，慢性病已成为全球70岁以 下人群死亡的主要原因。 "AI+慢病管理"能碰撞出怎样的火花？ 今年9月，方舟健客携杏石大模型登上《Nature》头版头条，《Nature》聚焦中国人工智能浪潮之下慢病 管理的创新模式，着重介绍了方舟健客杏石大模型的技术底座及其研发背景。 澳大利亚悉尼科技大学专注于中国创新研究的科技政策学者MarinaZhang指出："方舟健客是中国在医疗 健康领域探索AI应用的先行者，其正凭借AI技术的独特优势，切入此前未被充分开发的市场。此外， 这一探索也具有更深层价值，那就是为破解全球慢病管理难题注入创新力量。" 近年来，方舟健客更将原有平台迭代升级，构建起更专业、更智能、更高效的"方舟健客AI+H2H智慧 医疗新生态"（以下简称"AI+H2H新生态"），以优势AI技术驱动医患服务的升级，为患者带来从医院到 家庭的无缝医疗服务体验。 当下，AI技术已在方舟健客的医疗服务中实现全面渗透。其自主研发的杏石大模型集成多模态能力 ...

Onalysys 易观分析 2025年AI精准医疗市场专题分析 易观分析 2025年12月 本产品保密并受到版权法保护 Confidential and Protected by Copyright Laws Onalysys 易观分析 01 演进过程 AI精准医疗演进：从科研成果走向临床应用的平台转化 Omalysys 易观分析 国际：AI辅助诊断进入临 中国：统一数据标准，推 技术规范完善 床实践，个体化医疗入保 动科研成果向临床转化 2017-2019年 精准医疗战略提出 中国：基层整改，靶向药 2004-2016年 国际：各国提出基准医疗 基因科技起点 入保，医疗体制改革 1960-2003年 计划，聚焦科研积累，强 国际：精准医疗从科研向 调基因数据库的建设 国际：人类基因组完成 临床探索过度 05 中国：注重战略实施，政 中国：起步晚，实验技术 中国：自主研发起步，聚 策推进，平台搭建 薄弱，依赖国外科技 焦研究。借助国家科技计 04 划加快布局生命科学，相 关企业兴起 03 02 01 2025-12-8 激发科技与创新活力 3 精准医疗是融合基因检测、大数据与生物信息技术，通过识别疾病靶 点， ...

Core Insights - The integration of health weight management into the Healthy China initiative marks a significant shift towards national-level governance in a previously fragmented sector [1][3] - The Chinese weight loss market is projected to reach approximately 474.45 billion yuan by 2024, driven by rising obesity rates and health demands [1][3] - The collaboration between Ark Health and the China Food and Drug Quality Safety Promotion Association aims to establish a national dialogue on weight management, emphasizing regulatory and academic cooperation [3][17] Market Dynamics - The obesity rates among Chinese adults are alarming, with 34.3% classified as overweight and 16.4% as obese as of 2024, potentially rising to 65.3% by 2030 [1][5] - The global obesity epidemic is expected to see adult numbers increase from 524 million in 2010 to 1.13 billion by 2030, highlighting the urgent need for effective weight management solutions [5][10] Technological Integration - AI technology is positioned as a critical enabler for weight management, providing continuous behavioral interventions and dynamic nutritional guidance [5][6] - Ark Health's AI-driven ecosystem includes five specialized AI entities and applications that cover the entire lifecycle of chronic disease management, enhancing service delivery [6][12] Business Model and Financial Performance - Ark Health's "AI + H2H" business model has shown profitability, with a reported revenue of 1.494 billion yuan in the first half of 2025, marking a 12.9% year-on-year increase [12][15] - The company has established a robust user base with 5.28 million registered users and a monthly active user growth rate of 34.4%, indicating strong market engagement [15] Competitive Advantage - Ark Health's strategic focus on "AI + weight management" is built on a foundation of existing capabilities in chronic disease management, differentiating it from competitors still exploring business models [12][14] - The company has formed partnerships with over 1,650 suppliers and 980 pharmaceutical companies, ensuring a comprehensive supply chain for weight management services [15][17] Industry Outlook - The recent conference on weight management signifies a shift from isolated innovations to a more standardized approach across the industry, enhancing Ark Health's leadership position [17] - As health weight management becomes a national consensus, the potential for Ark Health's capital value and industry influence to grow remains significant [17]

Core Insights - Ark Health (06086) saw a significant increase of over 8%, reaching HKD 4.34 with a trading volume of HKD 40.77 million, following a report in Nature highlighting China's innovative chronic disease management model that integrates AI [1] Group 1: Industry Overview - The report in Nature emphasizes China's unique approach to chronic disease management, which effectively combines AI with various chronic disease management strategies, making it a rare example globally [1] - The emergence of new AI technologies, particularly large models, has created a new wave of innovation in the healthcare sector, with Ark Health positioned to capitalize on these trends [1] Group 2: Company Developments - Ark Health's "super digital brain," the Xing Shi large model, powers five major applications: AI medication assistant, AI health steward, AI doctor assistant, AI academic assistant, and AI search, each tailored for specific clinical and patient scenarios [2] - The AI academic assistant product enhances efficiency by providing expert-level answers with voice interaction capabilities, catering to the busy schedules of clinical doctors [2]

Group 1 - The core viewpoint of the articles highlights the significant rise of Ark Health (方舟健客) stock, which increased by 8.23% to HKD 4.34, with a trading volume of HKD 40.77 million, following a report in Nature about China's medical AI models [1] - The Nature report emphasizes China's chronic disease management model, which integrates AI with various chronic disease management practices, showcasing a successful case that is rare globally [1] - The report indicates that while there are few large-scale companies in the overseas market that deeply integrate AI with chronic disease management, China's innovative forces are emerging in this field, potentially allowing for a leapfrog development [1] Group 2 - Ark Health's "super digital brain," the Xing Shi model, drives five major applications: AI medication assistant, AI health manager, AI doctor assistant, AI academic assistant, and AI search, each tailored for specific clinical and patient scenarios [2] - Each application provides real-time and precise assistance in areas such as medication guidance, patient education, diagnostic support, and medical literature queries [2] - The AI academic assistant product enhances efficiency and user engagement by offering expert-level answers with voice interaction capabilities, catering to the busy clinical environment of doctors [2]

Major Events - China Power (02380) plans to acquire a 31% stake in Dazhou Energy [1] - Shun Teng International Holdings (00932) received a 20% discount from Chairman Zhang Shaohui for a full acquisition offer [1] - Huajian Medical (01931) established a joint venture to deepen the global blockchain financial ecosystem strategy through the "ETHK" core brand [1] - Derin Holdings (01709) signed a strategic cooperation and investment agreement with Winner Fashion (03709) [1] - Dongwu Cement (00695) major shareholder Goldview intends to sell a total of 204 million shares, making Hong Kong Aviation the single largest shareholder [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval for SYH2066 tablets in China [1] - GAC Group (02238) plans to issue up to 15 billion yuan in corporate bonds and 15 billion yuan in medium-term notes [1] - Huatai Securities (06886) plans to issue up to 6 billion yuan in corporate bonds [1] - Ark Health (06086) stated that the H2H conference news is not insider information and is unaware of the reason for the stock price increase [1] Financial Data - China Resources Land (01109) reported a cumulative contract sales amount of 136.8 billion yuan for the first eight months, a year-on-year decrease of 12.0% [1] - Yuexiu Property (00123) reported a cumulative contract sales amount of approximately 73.011 billion yuan for the first eight months, a year-on-year increase of approximately 3.7% [1] - Zhong An Online (06060) reported a total original insurance premium income of approximately 23.625 billion yuan for the first eight months, a year-on-year increase of 6.36% [1]

Core Insights - The board of Ark Health (06086.HK) noted a recent increase in the company's share price on September 12, 2025 [1] - The company announced its proprietary "Xing Shi" large model as a cornerstone for five flagship applications aimed at enhancing clinical diagnostic support and personalized chronic disease management [1] - Strategic partnerships were established with Innovent Biologics and Otsuka Pharmaceutical to integrate digital health solutions and improve patient outcomes in the growing weight management market in China [1] Summary by Categories - **Share Price Movement** - The board observed a rise in the company's share price on September 12, 2025 [1] - **Product Development** - The company launched the "Xing Shi" large model, which serves as the foundation for five key applications: AI Drug Assistant, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI Search [1] - **Strategic Partnerships** - A partnership with Innovent Biologics was formed to integrate Ark's digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model for personalized digital support [1] - Collaboration with Otsuka Pharmaceutical aims to combine AI technology with Otsuka's innovative drug portfolio to develop comprehensive digital solutions for drug support services and health education programs [1]

Core Viewpoint - Ark Health (06086) has observed a recent increase in its share price on the Hong Kong Stock Exchange as of September 12, 2025, following the announcement of its strategic initiatives and partnerships in the healthcare sector [1]. Group 1: Company Developments - The company has launched its proprietary "Xing Shi" large model, which serves as the foundation for five flagship applications, including AI medication assistant, AI health manager, AI doctor assistant, AI academic assistant, and AI search, aimed at enhancing clinical diagnostic support and personalized chronic disease management [1]. - Ark Health has formed a strategic partnership with Innovent Biologics to integrate its H2H digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model to provide personalized digital maintenance and adherence support for Innovent's Ma Shidu peptide in China's rapidly growing weight management market [1]. - The company has also entered into a strategic collaboration with Zhejiang Otsuka Pharmaceutical Co., combining its AI technology advantages with Otsuka's innovative drug portfolio to jointly develop comprehensive digital solutions covering drug support services, targeted patient outreach programs, and health education initiatives [1]. Group 2: Regulatory Confirmation - The board has confirmed that the information contained in the press release does not constitute inside information as defined under the Listing Rules and relevant securities regulations, and it is unaware of any reasons for the increase in share price or any information that needs to be disclosed to avoid creating a false market in its shares [2].

Group 1 - The company, Ark Health (06086), has observed a recent increase in its share price on the Hong Kong Stock Exchange as of September 12, 2025 [1] - The company announced its proprietary "Xing Shi" large model, which serves as the foundation for five flagship applications aimed at enhancing clinical diagnostic support and personalized chronic disease management [1] - A strategic partnership has been established with Innovent Biologics to integrate Ark's H2H digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model for personalized digital maintenance and compliance support in China's growing weight management market [1] - The company has also formed a strategic collaboration with Zhejiang Otsuka Pharmaceutical Co., Ltd. to develop comprehensive digital solutions that combine AI technology with Otsuka's innovative drug portfolio, focusing on drug support services, targeted patient outreach programs, and health education initiatives [1] Group 2 - The board confirmed that the information contained in the press release does not constitute insider information as defined under the relevant listing rules and securities regulations [2] - The board is not aware of any reasons for the increase in share price or any information that would require disclosure to prevent a false market in the shares [2]

Core Insights - Guangdong Province has registered 6 new generative artificial intelligence services, bringing the total to 23 registered services as of July 17 [1] Group 1: New Registrations - The newly registered generative AI services include: 1. Guangfa GPT Model by Guangfa Securities Co., Ltd., registered on July 10, 2025 [3] 2. Anli AI Assistant by Amway (China) Daily Products Co., Ltd., registered on July 10, 2025 [3] 3. Samsung Smart Assistant by Guangzhou Samsung Communication Technology Research Co., Ltd., registered on July 17, 2025 [3] 4. Xing Shi Large Model by Guangzhou Ark Cloud Health Information Technology Group Co., Ltd., registered on July 17, 2025 [3] 5. Zhongchang Kangda Education Large Model by Guangzhou Zhongchang Kangda Information Technology Co., Ltd., registered on July 17, 2025 [3] 6. Zhilv Plant Large Model by Guangzhou Jingli Garden Fragrance Technology Co., Ltd., registered on July 17, 2025 [3]